Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new
clinical data from an ongoing phase IIa study of simeprevir, odalasvir and AL
-335, being conducted by Alios BioPharma Inc., part of the Janssen
Pharmaceutical Companies of Johnson & Johnson (Janssen), will be presented at
the European Association for the Study of the Liver (EASL)/American Association
for the Study of Liver Diseases (AASLD) Special Conference entitled “New
Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure”. The
conference will take place in Paris, France, on September 23rd and 24th 2016.
The ePoster presentation, entitled “Short duration treatment with AL-335 and
odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients
with hepatitis C virus (HCV) genotype (GT) 1 infection”, will be made on Friday
September 23rd. It will include interim data which aims to establish the safety,
pharmacokinetics and efficacy (SVR12) of different combination regimens
consisting of three directly acting antiviral agents (DAAs), simeprevir,
odalasvir, an HCV NS5A inhibitor, and AL-335, a nucleotide inhibitor of the HCV
NS5B polymerase, for the treatment of GT 1 HCV infection in eight weeks or less.
Further information about the study is available at
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 14.00 CET on 11 August 2016.
Medivir is a research based pharmaceutical company with a research focus on
oncology and infectious diseases. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a portfolio of specialty care pharmaceuticals
on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.